Show simple item record

dc.creatorGiva, Sheiniz
dc.creatorAbdelrahim, Ahmed
dc.creatorOjinna, Blessing T.
dc.creatorPutrevu, Venkata Pravallika
dc.creatorBornemann, Elisa A.
dc.creatorFarhat, Hadi
dc.creatorAmaravadi, Kavya
dc.creatorAbdallah, Mahmoud Ben
dc.creatorGutlapalli, Sai Dheeraj
dc.creatorPenumetcha, Sai Sri
dc.date.accessioned2024-03-29T19:09:28Z
dc.date.available2024-03-29T19:09:28Z
dc.date.issued2022-12-16
dc.identifier.citationGiva S, Abdelrahim A, Ojinna B T, et al. (December 16, 2022) Safety and Efficacy of Mesenchymal Stem Cells for the Treatment of Evolving and Established Bronchopulmonary Dysplasia: A Systematic Literature Review. Cureus 14(12): e32598. doi:10.7759/cureus.32598
dc.identifier.issn2168-8184
dc.identifier.urihttp://hdl.handle.net/20.500.12613/10092
dc.description.abstractBronchopulmonary dysplasia (BPD) is a frequent sequela of modern medicine when infants are born prematurely. Currently, there is no single treatment or combination of treatments to prevent or fully treat BPD. Mesenchymal stem cells (MSCs) have promising properties that could aid in the reversal of lung injury, as seen in patients with BPD. This study reviews the available evidence regarding the safety and efficacy of the use of MSCs for the treatment of evolving and established BPD. This systematic review was performed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). We found eight studies that fulfilled the inclusion and exclusion criteria. While all studies proved the safety and efficacy of MSCs administered intravenously and intratracheally, the only available randomized controlled trial (RCT) failed to demonstrate the benefit of MSC administration in the early treatment of BPD. The remaining studies varied between phase I clinical trials and case reports, but all seemed to show some evidence that MSCs may be of benefit in the late treatment of established BPD. Considering some of the studies have less evidence, early treatment to prevent lung fibrosis may be more successful, particularly in the younger gestational ages where lung development is more immature, and research should focus on this.
dc.format.extent10 pages
dc.languageEnglish
dc.language.isoeng
dc.relation.ispartofFaculty/ Researcher Works
dc.relation.haspartCureus: Journal of Medical Science, Vol. 14
dc.relation.isreferencedbySpringer
dc.rightsAttribution CC BY
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.subjectRespiratory distress syndrome of prematurity
dc.subjectMesenchymal stem cells
dc.subjectStem cells
dc.subjectChronic lung disease of prematurity
dc.subjectBronchopulmonary dysplasia
dc.titleSafety and Efficacy of Mesenchymal Stem Cells for the Treatment of Evolving and Established Bronchopulmonary Dysplasia: A Systematic Literature Review
dc.typeText
dc.type.genreJournal article
dc.contributor.groupTemple University. Hospital
dc.relation.doihttp://dx.doi.org/10.7759/cureus.32598
dc.ada.noteFor Americans with Disabilities Act (ADA) accommodation, including help with reading this content, please contact scholarshare@temple.edu
dc.temple.creatorGiva, Sheiniz
refterms.dateFOA2024-03-29T19:09:28Z


Files in this item

Thumbnail
Name:
GivaEtAL-JournalArticle-2022-12.pdf
Size:
318.0Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record

Attribution CC BY
Except where otherwise noted, this item's license is described as Attribution CC BY